Anne Bruinvels joins EPEMED as executive director

Targeted with growing start-up organisation and building its strategic framework

The European Personalised Medicine Diagnostics Association (EPEMED) has appointed Anne Bruinvels, an entrepreneur in personalised healthcare, as executive director and board member.

Bruinvels will be responsible for growing the start-up organisation and, together with the board of directors, for building its strategic framework in creating guidance for all those involved in progressing personalised medicine with an emphasis on European market challenges.

‘I'm delighted to join EPEMED's board and to lead the association to facilitate the development and introduction of personalised medicine in Europe. I'm looking forward to working with the different parties worldwide involved in making real progress in this field,’ said Bruinvels.

Bruinvels started her work in personalised medicine more than 10 years ago. She previously founded Elixior, a personalised healthcare advisory company and prior to that Curidium, a personalised medicine company identifying companion diagnostics and therapeutics to treat patients with central nervous system disorders. She was Curidium's ceo for more than six years and raised several rounds of funding before taking the company public on the AIM of the London Stock Exchange.

Bruinvels has also worked in research for various pharmaceutical companies, including SmithKline Beecham, Wyeth and Sandoz Pharma.

You may also like

Design & Build

ESTEVE CDMO expands spray drying and high-potency containment capacity at Girona facility

ESTEVE CDMO has announced plans to add a 3000-square-metre production unit at its Celrà site in Spain to house additional spray drying equipment and high-potency containment suites, with the first new GEA spray dryer due online in Q1 2027
You need to be a subscriber to read this article.
Click here to find out more.
Finance

Oncoinvent patent win and CellCarta deal highlight IP power in oncology innovation

New patent protection for Radspherin and a global exclusivity deal for Aspyre Lung underline how strong IP strategies are driving competitive advantage in cancer therapeutics and diagnostics
Research & Development

ProImmune and Roslin Institute collaborate to develop species-specific Ankyron binders for veterinary immunology

Immunological reagents specialist ProImmune has partnered with the University of Edinburgh's Roslin Institute to generate and validate novel species-specific binding proteins for porcine, bovine, avian and salmonid research, addressing a critical shortage of high-quality veterinary immunology reagents
Research & Development

Siemens Healthineers launches blood-based pTau217 and BDTau research assays for Alzheimer's and neurological disease

Siemens Healthineers has made two automated brain biomarker assays available for research use, offering scientists a less invasive blood-based alternative to cerebrospinal fluid testing for investigating neurological disease progression and early Alzheimer's detection
You need to be a subscriber to read this article.
Click here to find out more.
Analysis

Semaglutide patent cliff: pharma industry braces for impact

With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
Manufacturing

Abzena named a leader in Frost & Sullivan ADC CDMO radar report

Recognition highlights integrated capabilities, proprietary technology and expertise in antibody-drug conjugates
Manufacturing

LabVantage Solutions introduces LabVantage CORTEX, advancing its LIMS platform for AI-driven laboratory operations

Next-Generation Platform Extends LIMS with Agentic AI and Cloud-Native Automation to Improve Efficiency, Reduce Errors and Gain Deeper Insight from Data. Learn More from LabVantage Leadership at Pittcon 2026
Subscribe now